{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T06:45:28Z","timestamp":1774075528972,"version":"3.50.1"},"reference-count":31,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,3,15]]},"DOI":"10.2169\/internalmedicine.5897-25","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T22:07:16Z","timestamp":1756332436000},"page":"782-787","source":"Crossref","is-referenced-by-count":0,"title":["Influence of Daily Salt Intake on Blood Pressure and Atrial Natriuretic Peptide Levels in Patients Treated with Sacubitril\/Valsartan"],"prefix":"10.2169","volume":"65","author":[{"given":"Takao","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Cardiology, International University of Health and Welfare Narita Hospital, Japan"},{"name":"Department of Cardiology, Toyosaka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Uonuma Kikan Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifusa","family":"Aizawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tachikawa General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Sorrentino MJ. The evolution from hypertension to heart failure. Heart Fail Clin 15: 447-453, 2019.","DOI":"10.1016\/j.hfc.2019.06.005"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation 134: 441-450, 2016.","DOI":"10.1161\/CIRCULATIONAHA.115.018912"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol 16: 223-237, 2020.","DOI":"10.1038\/s41581-019-0244-2"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Endo S, Mori T, Yoneki Y, et al. Blockade of angiotensin II type-1 receptor increases salt sensitivity in Sprague-Dawley rats. Hypertens Res 32: 513-519, 2009.","DOI":"10.1038\/hr.2009.40"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Lambers Heerspink HJ, Holtkamp FA, Parving HH, et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int 82: 330-337, 2012.","DOI":"10.1038\/ki.2012.74"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. McMurray JJV, Packer M, Desai AS, et al.; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371: 993-1004, 2014.","DOI":"10.1056\/NEJMoa1409077"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Gupta DK, Wang TJ. Natriuretic peptides and cardiometabolic health. Circ J 79: 1647-1655, 2015.","DOI":"10.1253\/circj.CJ-15-0589"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J 34: 886-893c, 2013.","DOI":"10.1093\/eurheartj\/ehs262"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Gardner DG, Chen S, Glenn DJ, Grigsby CL. Molecular biology of the natriuretic peptide system: implications for physiology and hypertension. Hypertension 49: 419-426, 2007.","DOI":"10.1161\/01.HYP.0000258532.07418.fa"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Murphy SP, Prescott MF, Camacho A, et al. Atrial natriuretic peptide and treatment with sacubitril\/valsartan in heart failure with reduced ejection fraction. JACC Heart Fail 9: 127-136, 2021.","DOI":"10.1016\/j.jchf.2020.09.013"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Uzu T, Sakaguchi M, Yokomaku Y, et al. Effects of high sodium intake and diuretics on the circadian rhythm of blood pressure in type 2 diabetic patients treated with an angiotensin II receptor blocker. Clin Exp Nephrol 13: 300-306, 2009.","DOI":"10.1007\/s10157-009-0157-7"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Tanaka T, Okamura T, Miura K, et al. A simple method to estimate populational 24-h urinary sodium and potassium excretion using a casual urine specimen. J Hum Hypertens 16: 97-103, 2002.","DOI":"10.1038\/sj.jhh.1001307"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Efficacy of sacubitril\/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study. Hypertens Res 45: 824-833, 2022.","DOI":"10.1038\/s41440-021-00819-7"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Wang TD, Tan RS, Lee HY, et al. Effects of sacubitril\/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension. Hypertension 69: 32-41, 2017.","DOI":"10.1161\/HYPERTENSIONAHA.116.08484"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Jackson AM, Jhund PS, Anand IS, et al. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J 42: 3741-3752, 2021.","DOI":"10.1093\/eurheartj\/ehab499"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Guyton AC, Coleman TG, Young DB, Lohmeier TE, DeClue JW. Salt balance and long-term blood pressure control. Annu Rev Med 31: 15-27, 1980.","DOI":"10.1146\/annurev.me.31.020180.000311"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Uzu T, Kimura G. Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 100: 1635-1638, 1999.","DOI":"10.1161\/01.CIR.100.15.1635"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Horio T, Iwashima Y, Yoshiyama M, Fukuda D, Rai T, Fujimoto K. Plasma renin activity as a marker for predicting the antihypertensive effect of switching to sacubitril\/valsartan in treated hypertensive patients: usefulness in daily clinical practice. J Clin Hypertens (Greenwich) 26: 1196-1200, 2024.","DOI":"10.1111\/jch.14900"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Sharma AM, Schorr U, Oelkers W, Distler A. Effects of sodium salts on plasma renin activity and norepinephrine response to orthostasis in salt-sensitive normotensive subjects. Am J Hypertens 6: 780-785, 1993.","DOI":"10.1093\/ajh\/6.9.780"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Lopez MJ, Wong SK, Kishimoto I, et al. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 378: 65-68, 1995.","DOI":"10.1038\/378065a0"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 27: 47-72, 2006.","DOI":"10.1210\/er.2005-0014"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kuhn M. Molecular physiology of membrane guanylyl cyclase receptors. Physiol Rev 96: 751-804, 2016.","DOI":"10.1152\/physrev.00022.2015"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Mattson DL, Lu S, Roman RJ, Cowley AW Jr. Relationship between renal perfusion pressure and blood flow in different regions of the kidney. Am J Physiol 264: R578-R583, 1993.","DOI":"10.1152\/ajpregu.1993.264.3.R578"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Lu S, Roman RJ, Mattson DL, Cowley AW Jr. Renal medullary interstitial infusion of diltiazem alters sodium and water excretion in rats. Am J Physiol  263: R1064-R1070, 1992.","DOI":"10.1152\/ajpregu.1992.263.5.R1064"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kiberd BA, Larson TS, Robertson CR, Jamison RL. Effect of atrial natriuretic peptide on vasa recta blood flow in the rat. Am J Physiol 252: F1112-F1117, 1987.","DOI":"10.1152\/ajprenal.1987.252.6.F1112"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Hynynen M, Kupari M, Salmenper\u00e4 M, et al. Hemodynamic effects of alpha-human atrial natriuretic peptide in healthy volunteers. J Cardiovasc Pharmacol 11: 711-715, 1988.","DOI":"10.1097\/00005344-198806000-00012"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Tokudome T, Otani K, Mao Y, et al. Endothelial natriuretic peptide receptor 1 play crucial role for acute and chronic blood pressure regulation by atrial natriuretic peptide. Hypertension 79: 1409-1422, 2022.","DOI":"10.1161\/HYPERTENSIONAHA.121.18114"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J 34: 886-893, 2013.","DOI":"10.1093\/eurheartj\/ehs262"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Sugiura T, Takase H, Ohte N, Dohi Y. Dietary salt intake increases with age in Japanese adults. Nutr Res 89: 1-9, 2021.","DOI":"10.1016\/j.nutres.2021.02.002"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Volpe M, Tritto C, De Luca N, et al. Failure of atrial natriuretic factor to increase with saline load in patients with dilated cardiomyopathy and mild heart failure. J Clin Invest 88: 1481-1489, 1991.","DOI":"10.1172\/JCI115458"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Iervasi G, Clerico A, Berti S, et al. Altered tissue degradation and distribution of atrial natriuretic peptide in patients with idiopathic dilated cardiomyopathy and its relationship with clinical severity of the disease and sodium handling. Circulation 91: 2018-2027, 1995.","DOI":"10.1161\/01.CIR.91.7.2018"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/6\/65_5897-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:33:36Z","timestamp":1774064016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/6\/65_5897-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,15]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5897-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,15]]},"article-number":"5897-25"}}